Moderna's Coronavirus Vaccine Candidate Advances to Regulatory Review in Canada
Moderna's (NASDAQ: MRNA) coronavirus vaccine candidate is now under regulatory inspection north of our border. The company announced Tuesday morning that it has initiated a "rolling submission" of mRNA-1273 with Health Canada, the country's healthcare authority.
The "rolling" adjective means that a regulatory body is reviewing a submittal while it is still undergoing clinical testing. The regulator parses and analyzes data from the study or studies as it comes in, and makes its decision whether or not to approve a candidate when it feels it has received sufficient information to do so.
Image source: Getty Images.
Source Fool.com
